Iovance Biotherapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon or good morning, anywhere you are. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. I just want to thank everyone for taking time out of their day today to listen to Iovance.
And if you have questions for institutional investors, please e-mail me to [email protected], or you can ping me on Bloomberg. It gives me great pleasure to introduce Iovance. We've got Maria Fardis, CEO. And just as a kind of introductory question, if you could maybe just talk through the differentiation and kind of the core competencies of Iovance in the oncology T cell space. Thank you.
Certainly. Thank you, Peter, for the invitation. Good afternoon, good morning to you.
So Iovance is developing a tumor infiltrating lymphocyte for treatment of solid tumors. These are cells that normally would come to the site
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
